Do BRCA1 and BRCA2 Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer

• Published in: Journal of clinical oncology Vol. 31; no. 31; pp. 3920 - 3925
• Main Authors: COLLINS, Ian M, MILNE, Roger L, MCLACHLAN, Sue Anne, FRIEDLANDER, Michael, HICKEY, Martha, WEIDEMAN, Prue C, BIRCH, Kate E, HOPPER, John L, PHILLIPS, Kelly-Anne
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Society of Clinical Oncology 01.11.2013
• Subjects: Adult; Biological and medical sciences; Cohort Studies; Female; Foundations; Genes, BRCA1; Genes, BRCA2; Gynecology. Andrology. Obstetrics; Heterozygote; Humans; Mammary gland diseases; Medical sciences; Menopause - genetics; Middle Aged; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Mutation; Proportional Hazards Models; Tumors; Breast disease; Menopause; Breast cancer; Malignant tumor; Research; Mammary gland diseases; Cancerology; BRCA2 gene; Familial cancer; Genetics; Mutation; Carrier; BRCA1 gene; Cancer; Tumor suppressor gene
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2013.49.3007

Limited data suggest that germline BRCA1 mutations are associated with occult primary ovarian insufficiency and that BRCA1 and BRCA2 mutation carriers might have earlier natural menopause (NM) than their noncarrier relatives. Eligible women were mutation carriers and noncarriers from families segregating a BRCA1 or BRCA2 mutation. Data were self-reported using uniform questionnaires at cohort entry and every 3 years thereafter. NM was defined as the cessation of menses for 12 months without another cause. Cox proportional hazards analysis modeled time from birth to NM, adjusting for multiple potential confounders. Analysis time was censored at the earliest of the following: last follow-up, bilateral oophorectomy, hysterectomy, commencement of hormone therapy, insertion of intrauterine device, or any cancer diagnosis. Hazard ratios (HRs) were estimated as a measure of how likely mutation carriers are, relative to noncarriers, to reach NM at a given age. A total of 1,840 women were eligible for analysis. Overall only 19% reached NM. A lower proportion of BRCA1 and BRCA2 mutation carriers reached NM compared with noncarriers. Conversely, a higher proportion of mutation carriers were censored at cancer diagnosis or oophorectomy than noncarriers. The adjusted HR estimates for NM were 1.03 (95% CI, 0.75 to 1.40; P = .9) for 445 BRCA1 mutation carriers and 559 noncarrier relatives and 1.01 (95% CI, 0.71 to 1.42; P = .9) for 374 BRCA2 mutation carriers and 462 noncarrier relatives. We found no evidence that BRCA1 and BRCA2 mutation carriers are at higher risk of NM at a given age than their noncarrier relatives.